We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BFLY's Blind-Sweep Ultrasound AI Tool for Gestational Age Wins FDA Nod
Read MoreHide Full Article
Key Takeaways
BFLY secured FDA clearance for its AI-powered blind-sweep GA Tool in handheld ultrasound devices.
BFLY's tool estimates gestational age in under two minutes using automated scans and deep-learning models.
Butterfly Network targets rural U.S. and low-resource regions, expanding access to prenatal imaging services.
Butterfly Network (BFLY - Free Report) recently secured clearance from the FDA for its fully automated Gestational Age (GA) Tool. This tool is integrated into its handheld ultrasound device and represents the first FDA-cleared AI-powered blind-sweep ultrasound solution designed to estimate gestational age.
Per management, enhancing maternal health outcomes and improving access to prenatal imaging are urgent global needs. BFLY is proud to introduce this innovative technology to mothers worldwide. With FDA clearance secured, the company now offers an AI-powered solution that can improve maternal healthcare both in the United States and globally by addressing persistent gaps in timely and reliable imaging, enabling earlier and better-informed clinical decisions.
Steve Cashman, Chief Business Officer, explained that the GA Tool is designed to serve three critical purposes: supporting rapid decision-making in emergency situations when gestational age is unknown, increasing access to care in regions with high maternal and neonatal mortality rates and enhancing the availability of prenatal ultrasound services in rural areas of the United States, where patients often face long travel times. The tool aims to help clinicians make quicker, earlier and confident decisions in critical situations.
BFLY Stock Trend Following the News
Shares of BFLY have gained 5.5% since the announcement on Monday. So far this year, the stock surged 72.6% against the industry’s 28.9% decline. However, the S&P 500 has risen 15.1% during the same timeframe.
In the long run, Butterfly Network stands to benefit from the FDA clearance of its AI-powered gestational age tool. As the first approved blind-sweep ultrasound solution, it strengthens the company’s innovation leadership and differentiates its platform in a competitive imaging market. The tool expands BFLY’s addressable market across underserved U.S. rural regions and low-resource global settings, accelerating adoption of its handheld devices and cloud software. Backed by deployments in Africa and support from the Gates Foundation, the clearance enhances revenue growth potential while reinforcing its role in advancing accessible maternal healthcare.
BFLY currently has a market capitalization of $975.24 million.
Image Source: Zacks Investment Research
More on the News
Timely and accurate assessment of GA is fundamental to effective prenatal care, yet in the United States, nearly half of rural counties lack hospital-based obstetric services, leaving many patients without easy access to essential imaging. On a global level, 92% of maternal and neonatal deaths occur in low- and middle-income countries, often due to preventable causes linked to limited access to basic diagnostic tools.
Butterfly Network is addressing this critical need with its AI-powered GA Tool. Built on deep-learning models developed in collaboration with researchers at the University of North Carolina at Chapel Hill, the tool uses a blind-sweep ultrasound method to estimate gestational age in under two minutes. The process is simple and automated — requiring only fundal height input, gel application and guided probe sweeps, eliminating the need for complex image capture or specialist interpretation.
Trained on more than 21 million ultrasound images across diverse populations, the model delivers results comparable to traditional sonographer-led assessments for pregnancies between 16 and 37 weeks. By reducing user variability and simplifying workflows, the tool empowers frontline healthcare providers to make faster, more informed decisions in emergencies or low-resource settings.
Already deployed in countries like Malawi and Uganda, the solution has been supported in part by funding from the Gates Foundation. With FDA clearance now in place, BFLY is well-positioned to expand access across Sub-Saharan Africa and underserved regions in the United States.
Industry Prospects Favoring the Market
Going by the data provided by Fortune Business Insights, the fetal monitoring market is valued at $3.46 billion in 2026 and is expected to witness a CAGR of 5.8% through 2034.
Factors like the increasing incidence of high-risk pregnancies and advancements in technology are driving market growth.
Other News
In February, Butterfly Network announced that its Butterfly iQ+/iQ3 systems and Compass AI ultrasound platform have received GovRAMP and TX-RAMP authorizations. These certifications enable the company to offer its cloud-based services to all state and local government agencies, including those in the state of Texas.
In January, Butterfly Network announced plans to launch its Beam Steering API. Expected in the first half of 2026, the API will support advanced third-party AI development as part of the company’s Butterfly Garden and Ultrasound-on-Chip co-development initiatives. This release will provide external developers with access to iQ Slice and iQ Fan, which were previously limited to BFLY’s own applications.
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Inspire Medical Systems (INSP - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Inspire Medical Systems, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted EPS of $1.65, beating the Zacks Consensus Estimate by 139.1%. Revenues of $269.1 million were in line with the Zacks Consensus Estimate.
INSP has an estimated long-term earnings growth rate of 10.6% compared with the industry’s 29.7% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 185.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BFLY's Blind-Sweep Ultrasound AI Tool for Gestational Age Wins FDA Nod
Key Takeaways
Butterfly Network (BFLY - Free Report) recently secured clearance from the FDA for its fully automated Gestational Age (GA) Tool. This tool is integrated into its handheld ultrasound device and represents the first FDA-cleared AI-powered blind-sweep ultrasound solution designed to estimate gestational age.
Per management, enhancing maternal health outcomes and improving access to prenatal imaging are urgent global needs. BFLY is proud to introduce this innovative technology to mothers worldwide. With FDA clearance secured, the company now offers an AI-powered solution that can improve maternal healthcare both in the United States and globally by addressing persistent gaps in timely and reliable imaging, enabling earlier and better-informed clinical decisions.
Steve Cashman, Chief Business Officer, explained that the GA Tool is designed to serve three critical purposes: supporting rapid decision-making in emergency situations when gestational age is unknown, increasing access to care in regions with high maternal and neonatal mortality rates and enhancing the availability of prenatal ultrasound services in rural areas of the United States, where patients often face long travel times. The tool aims to help clinicians make quicker, earlier and confident decisions in critical situations.
BFLY Stock Trend Following the News
Shares of BFLY have gained 5.5% since the announcement on Monday. So far this year, the stock surged 72.6% against the industry’s 28.9% decline. However, the S&P 500 has risen 15.1% during the same timeframe.
In the long run, Butterfly Network stands to benefit from the FDA clearance of its AI-powered gestational age tool. As the first approved blind-sweep ultrasound solution, it strengthens the company’s innovation leadership and differentiates its platform in a competitive imaging market. The tool expands BFLY’s addressable market across underserved U.S. rural regions and low-resource global settings, accelerating adoption of its handheld devices and cloud software. Backed by deployments in Africa and support from the Gates Foundation, the clearance enhances revenue growth potential while reinforcing its role in advancing accessible maternal healthcare.
BFLY currently has a market capitalization of $975.24 million.
Image Source: Zacks Investment Research
More on the News
Timely and accurate assessment of GA is fundamental to effective prenatal care, yet in the United States, nearly half of rural counties lack hospital-based obstetric services, leaving many patients without easy access to essential imaging. On a global level, 92% of maternal and neonatal deaths occur in low- and middle-income countries, often due to preventable causes linked to limited access to basic diagnostic tools.
Butterfly Network is addressing this critical need with its AI-powered GA Tool. Built on deep-learning models developed in collaboration with researchers at the University of North Carolina at Chapel Hill, the tool uses a blind-sweep ultrasound method to estimate gestational age in under two minutes. The process is simple and automated — requiring only fundal height input, gel application and guided probe sweeps, eliminating the need for complex image capture or specialist interpretation.
Trained on more than 21 million ultrasound images across diverse populations, the model delivers results comparable to traditional sonographer-led assessments for pregnancies between 16 and 37 weeks. By reducing user variability and simplifying workflows, the tool empowers frontline healthcare providers to make faster, more informed decisions in emergencies or low-resource settings.
Already deployed in countries like Malawi and Uganda, the solution has been supported in part by funding from the Gates Foundation. With FDA clearance now in place, BFLY is well-positioned to expand access across Sub-Saharan Africa and underserved regions in the United States.
Industry Prospects Favoring the Market
Going by the data provided by Fortune Business Insights, the fetal monitoring market is valued at $3.46 billion in 2026 and is expected to witness a CAGR of 5.8% through 2034.
Factors like the increasing incidence of high-risk pregnancies and advancements in technology are driving market growth.
Other News
In February, Butterfly Network announced that its Butterfly iQ+/iQ3 systems and Compass AI ultrasound platform have received GovRAMP and TX-RAMP authorizations. These certifications enable the company to offer its cloud-based services to all state and local government agencies, including those in the state of Texas.
In January, Butterfly Network announced plans to launch its Beam Steering API. Expected in the first half of 2026, the API will support advanced third-party AI development as part of the company’s Butterfly Garden and Ultrasound-on-Chip co-development initiatives. This release will provide external developers with access to iQ Slice and iQ Fan, which were previously limited to BFLY’s own applications.
Butterfly Network, Inc. Price
Butterfly Network, Inc. price | Butterfly Network, Inc. Quote
BFLY’s Zacks Rank & Key Picks
Currently, BFLY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Inspire Medical Systems (INSP - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Inspire Medical Systems, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted EPS of $1.65, beating the Zacks Consensus Estimate by 139.1%. Revenues of $269.1 million were in line with the Zacks Consensus Estimate.
INSP has an estimated long-term earnings growth rate of 10.6% compared with the industry’s 29.7% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 185.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.